Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
15.00
-0.45 (-2.91%)
At close: Apr 28, 2026
158.62%
Market Cap 1.08B
Revenue (ttm) n/a
Net Income (ttm) -77.13M
Shares Out 48.35M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,150
Average Volume 45,584
Open 15.40
Previous Close 15.45
Day's Range 15.00 - 15.50
52-Week Range 1.80 - 17.85
Beta 0.38
RSI 51.83
Earnings Date May 28, 2026

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. The company develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. It is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

Curasight Transcript: Investor Update

A rights issue seeks up to DKK 100 million to fund pivotal studies in brain and prostate cancer, with about half already secured from investors and management. The capital will extend runway to H2 2026, support key clinical milestones, and enhance partnership opportunities.

1 year ago - Transcripts

Curasight Transcript: Status Update

2 years ago - Transcripts